BMY 45778
- Product Name
- BMY 45778
- CAS No.
- 152575-66-1
- Chemical Name
- BMY 45778
- Synonyms
- BMY 45778;BMY 45778 >=98% (HPLC);[3-(4,5-DIPHENYL[2,4'-BIOXAZOL]-5'-YL)PHENOXY]ACETIC ACID;Acetic acid, 2-[3-(4,5-diphenyl[2,4'-bioxazol]-5'-yl)phenoxy]-
- CBNumber
- CB6723653
- Molecular Formula
- C26H18N2O5
- Formula Weight
- 438.43
- MOL File
- 152575-66-1.mol
BMY 45778 Property
- Boiling point:
- 659.9±65.0 °C(Predicted)
- Density
- 1.298±0.06 g/cm3(Predicted)
- storage temp.
- room temp
- solubility
- ≥67.6 mg/mL in DMSO
- form
- powder
- pka
- 3.10±0.10(Predicted)
- color
- white to beige
N-Bromosuccinimide Price
- Product number
- BM0032
- Product name
- BMY 45778
- Purity
- ≥98% (HPLC)
- Packaging
- 25mg
- Price
- $402
- Updated
- 2022/05/15
- Product number
- 1442
- Product name
- BMY 45778
- Purity
- ≥99%(HPLC)
- Packaging
- 50
- Price
- $587
- Updated
- 2021/12/16
- Product number
- B596418
- Product name
- BMY 45778
- Packaging
- 2.5mg
- Price
- $175
- Updated
- 2021/12/16
- Product number
- B6741
- Product name
- BMY 45778
- Packaging
- 10mg
- Price
- $213
- Updated
- 2021/12/16
- Product number
- KIN0008616
- Product name
- BMY 45778
- Purity
- 95.00%
- Packaging
- 10MG
- Price
- $709.46
- Updated
- 2021/12/16
BMY 45778 Chemical Properties,Usage,Production
Uses
BMY 45778 is an agonist for IP receptor to up-regulate the expression of C?/EBPβ and C?/EBPδ.
Definition
ChEBI: BMY 45778 is a bisoxazole. It has a role as a partial prostacyclin agonist.
Biological Activity
Non-prostanoid prostacyclin mimetic that acts as a partial agonist at IP 1 prostacyclin receptors. Potently inhibits platelet aggregation in vitro (IC 50 = 27-35 nM).
Biochem/physiol Actions
BMY 45778 is a non-prostanoid prostacyclin agonist.
References
[1]. seiler sm, brassard cl, federici me, et al. [3-[4-(4,5-diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (bmy 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, camp levels, protein kinase, and iloprost binding. prostaglandins, 1997, 53(1): 21-35.
[2]. wise h, qian ym, jones rl. a study of prostacyclin mimetics distinguishes neuronal from neutrophil ip receptors. eur j pharmacol, 1995, 278(3): 265-269.